CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase I/II Study of Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (CYNK-001) for the Treatment of Adults With COVID-19

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT04365101
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:38:38.379966+00:00
Published At: 2022-05-25T00:00:00+00:00
Record Updated At: 2022-05-25
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Coronavirus", "Coronavirus Infection", "Severe Acute Respiratory Syndrome Coronavirus 2", "Pneumonia", "Pneumonia, Viral", "Lung Diseases", "Respiratory Tract Disease", "Respiratory Tract Infections", "Coronaviridae Infections", "Nidovirales Infections", "RNA Virus Infections", "Virus Disease", "Immunologic Disease", "ARDS", "Immunologic Factors", "Physiological Effects of Drugs", "Antiviral Agents", "Anti-infective Agents", "Analgesics", "Antimetabolites, Antineoplastic"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2022-05-25"
protocolSection.identificationModule.nctId: "NCT04365101"
protocolSection.identificationModule.officialTitle: "A Phase I/II Study of Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (CYNK-001) for the Treatment of Adults With COVID-19"
protocolSection.statusModule.overallStatus: "UNKNOWN"
protocolSection.designModule.phases: ["PHASE1", "PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.